Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762)
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00002154/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the immunogenicity and safety of GSK's trivalent MMR (Priorix®), comparing it to Merck"s MMR vaccine (M-M-R®II), which is approved for use in the US.
提供机构：
Vivli
创建时间：
2018-10-27
